NewsRadio WFLA (WFLA-AM)
NewsRadio WFLA (WFLA-AM)
KENNETH RAPOZA – INDIAN DRUG COMPANY FAILS FDA INSPECTION 5 25 24
KENNETH RAPOZA – INDIAN DRUG COMPANY FAILS FDA INSPECTION 5 25 24
KENNETH RAPOZA – INDIAN DRUG COMPANY FAILS FDA INSPECTION 5 25 24
Saturday 25th May 2024
Kenneth Rapoza discusses the fallout of an FDA inspection failure at an Indian pharmaceutical company and its impact on U.S. drug shortages and safety.
Explicit
11 minutes
Informative
Thought-provoking
Eye-opening
Educational
Supportive
About this podcast
Author:
NewsRadio WFLA (WFLA-AM)
Overview:
Categories:
Innovative Treatments & Recovery Paths
Holistic Health Innovations
Innovative Healing Arts
Sexual Stigmas & Myths
Mindful Recovery
Links:
Visit site
Episodes:
1002 (View all)
Do you want to link to this podcast?
Get the buttons here!FDA Failures and Drug Shortages: What’s Really Happening?
Episode Overview
- FDA challenges in balancing safety and drug supply
- Impact of FDA inspection failure on Indian pharmaceutical company
- Dominance of Indian companies in the U.S. generics market
- Concerns over drug shortages and safety regulations
- Need for greater oversight in pharmaceutical manufacturing
The FDA is absolutely in a rock and a hard place because they have to balance those two things: safety and supply. The United States has about 320 drugs that we take regularly or that hospitals use every day in surgeries that we don't make here.
Ever wondered what happens when a pharmaceutical company fails an FDA inspection? In this episode of 'American Medicine Today', Kenneth Rapoza, an industry analyst from the Coalition for a Prosperous America, takes us behind the scenes of a recent inspection failure at an Indian drug company. This isn't just a bureaucratic hiccup; it has real-world consequences for drug shortages and patient safety in the U.S.
Kenneth, who’s also a former Wall Street Journal correspondent, breaks down the ten requirements the company failed to meet and why these lapses matter. He discusses the dominance of Indian companies in the U.S. generics market and the ripple effects of relying heavily on foreign drug suppliers. The conversation also raises critical questions about the balance between maintaining stringent safety standards and ensuring a steady drug supply.
If you're curious about how these issues affect your health and safety, this episode is a must-listen. It’s an eye-opener that blends expert insights with real-world implications, making it accessible and engaging for anyone concerned about healthcare.